Cited by 28Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsArtificial Intelligence in Healthcare

Deep Learning Based Multimodal Progression Modeling for Alzheimer’s Disease

Yang, Liuqing, Wang, Xifeng, Guo, Qi, Gladstein, Scott, Wooten, Dustin, Li, Tengfei, Robieson, Weining Z, Sun, Yan +2 more·2021·Statistics in Biopharmaceutical Research

Abstract

The progression of Alzheimer’s disease (AD) is a continuous process in cognitive and biomarker changes, with only a fraction of mild cognitive impairment (MCI) patients eventually advancing to AD. There is no definite biomarker signature to determine this eventual progress. The discovery and development of prognostic biomarker signatures for AD is essential to address the challenges of AD drug discovery and development. The deep learning (DL) technique is a recent breakthrough in data science that enables researchers to discover previously unknown features comprised by complicated patterns learnt from large datasets. It has outperformed many traditional machine learning methods in computer vision tasks. In this article, we evaluated the performance of DL algorithms in differentiating patients with diagnosis of AD, MCI, or no evidence of dementia using baseline MRI data of the brain, and integrated features extracted from the neural network with other baseline biomarkers to develop an AD prognostic signature. This signature can be used to understand the patient heterogeneity in a study cohort and provide enrichment strategies for AD clinical trial design.

Integrity signals

Registry

Crossref · 10.1080/19466315.2021.1884129

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Yang, L., Wang, X., Guo, Q., Gladstein, S., Wooten, D., Li, T., Robieson, W. Z., Sun, Y., Huang, X., & Initiative, F. T. A. D. N.
Affiliations
  • AbbVie (United States) (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Huang, Xin
Venue
Statistics in Biopharmaceutical Research
Published
2021-03-10
Volume
13
Issue
3
Pages
337-343
ISSN
1946-6315 (ISSN-L)
OpenAlex
W3129113421
Cited by
28
References
30
Citations by year
2026: 4 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 2 · 2021: 2
FWCI
3.05
Type
journal article
Language
en
Open access
closed
Locations
Statistics in Biopharmaceutical Research (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Health Professions › Health Information Management › Artificial Intelligence in Healthcare
Keywords
Alzheimer's disease, mild cognitive impairment, disease progression, prognostic factors, multimodal biomarker integration, baseline MRI, deep feature extraction, patient heterogeneity, clinical trial enrichment, dementia diagnosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review